Showing posts with label prostate. Show all posts
Showing posts with label prostate. Show all posts

Tuesday, September 29, 2009

Study: PSA Test Considered Unreliable Prostate Cancer Screening

Researchers noted that the inability of the PSA test to distinguish between deadly and harmless prostate cancers makes it unusable as a population-wide screening tool.  PSA is a protein made by the prostate gland. It is found in small amounts in the blood of healthy men, and is often elevated in men with prostate cancer, but also in men with benign prostate enlargement.

 Some 745,000 men in the United States will be diagnosed with cancer this year according to the American Association for Critical Illness Insurance, the industry trade group.  Nearly 300,000 will die and prostate cancer causes about a quarter of all cancer deaths among men.

The lead author of one study, a urologist with Gavle Hospital in Gavle, Sweden, noted that in addition to PSA, further biomarkers are needed before inferring population-based screening for prostate cancer.  The claim was based on a study of PSA tests of over 500 men diagnosed with prostate cancer. Their PSA was measured several years before being diagnosed. Scientists compared those tests with PSA tests from over 1,000 men without prostate cancer.

Reserachers reported that in men with a prediagnostic PSA level below 1 nanogram per milliliter, only six men [1.2 percent] were later diagnosed with a high-risk prostate cancer. Hence, PSA levels below [that] almost ruled out a future high-risk prostate cancer diagnosis.  They noted that the direct implication of their findings in a screening situation was that no matter which PSA cut-off you adopt for selecting men for further diagnostic work-up, you will either have too many false positives or too many false negatives.

Given the current trend in lowering the PSA cut-off to about 3 nanograms per milliliter, the medical reserachers noted that a large number of healthy men will be subject to painful, stressful and costly diagnostic procedures.  Their report worried that the wide overdiagnosis of slow-growing tumors causing unnecessary medical treatment and anxiety.

Although most agencies providing recommendations on prostate cancer screening, especially those outside the United States, do not recommend routine PSA testing for the early detection of prostate cancer, it continues to be performed frequently medical experts noted.

Thursday, September 24, 2009

Aspirin Protects Against Colon Cancer

An aspirin a day can prevent colon cancer in people with a genetic disorder that increases their risk of developing the disease.

Colorectal is the second biggest cause of cancer death in the United States and Europe, where a total of 560,000 people develop the disease each year, and 250,000 die from it according to the American Association for Critical Illness insurance, the national trade organization.

Scientists at the Institute of Human Genetics at Newcastle University in Britain said the benefits of aspirin were only seen after several years.  The researchers noted that they uncovered a simple way of controlling stems cells that make tumors grow.

The researchers tested over 1,000 people with Lynch syndrome -- an inherited condition that predisposes a person to a range of cancers, particularly of the colon.  Some were given aspirins and some a placebo.

Follow-up tests after 10 years showed that although there was no difference in cancer rates after 29 months, a significant difference was detected after four years.  Fewer people in the aspirin group developing colon cancer, the study's leader noted.

To date, there have been only six colon cancers in the aspirin group as opposed to 16 who took placebo, the study notes.  There is also a reduction in endometrial cancer.

People with Lynch syndrome have an increased risk of many cancers including stomach, colon, brain, skin, and prostate. Women carriers also have a high risk of developing endometrial and ovarian cancers.

In low daily doses aspirin has been found to stave off the risk of heart attacks and strokes, as well as chase away occasional aches and pains.  Other scientists have previously found it can reduce the risk of developing colon cancer and suggested it does so by blocking the enzyme cyclooxygenase2, or COX-2, which promotes inflammation and cell division and is found in high levels in tumors.

Wednesday, September 23, 2009

Prostate Cancer Treatment May Spark Heart Problems

The findings from new research conducted at King's College in London could make doctors think twice before prescribing the standard hormone treatment to men with prostate cancer, particularly if they are at risk of heart disease.

More than 670,000 men are diagnosed with prostate cancer globally every year, making it the second-most common cancer in men, after lung cancer.   In the U.S., over 185,000 men are diagnosed with prostate cancer annually according to the American Association for Critical Illness Insurance, the national trade organization. About 600,000 men are being treated with endocrine therapies for prostate cancer worldwide.

Researchers studied 30,000 men in Sweden with prostate cancer who received hormone therapy between 1997 and 2006. They compared the rate of heart problems in those patients to the rate in the general Swedish population. Prostate cancer patients had a 28 percent higher relative chance of having a fatal heart attack and a 21 percent increased chance of dying from heart disease.

While these risks were still low in absolute terms, the researchers estimated that the hormone therapies would cause heart problems including a heart attack at the rate of about 10 persons for every 1,000 prostate cancer patients.

Previous studies have found hormone therapy given to prostate cancer patients with a history of heart disease increases their chances of dying. Scientists believe that male-produced testosterone has some protective effect on the heart. Thus, hormones that interfere with testosterone could be deadly.